Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury

Circulation. 2003 May 6;107(17):2238-43. doi: 10.1161/01.CIR.0000063577.32819.23. Epub 2003 Apr 28.

Abstract

Background: Receptor for advanced-glycation end products (RAGE) and its ligands AGEs and S100/calgranulins have been implicated in a range of disorders. However, the role of RAGE/ligand interaction in neointimal hyperplasia after vascular injury remains unclear.

Methods and results: We examined the expression of RAGE and its ligands after balloon injury of the carotid artery in both Zucker diabetic and nondiabetic rats. Using a soluble portion of the extracellular domain of RAGE, we determined the effects of suppressing RAGE/ligand interaction on vascular smooth muscle cell (VSMC) proliferation and neointimal formation after arterial injury. We demonstrate a significantly increased accumulation of AGE and immunoreactivities of RAGE and S100/calgranulins in response to balloon injury in diabetic compared with nondiabetic rats. Blockade of RAGE/ligand interaction significantly decreased S100-stimulated VSMC proliferation in vitro and bromodeoxyuridine (BrdU)-labeled proliferating VSMC in vivo, and suppressed neointimal formation and increased luminal area in both Zucker diabetic and nondiabetic rats.

Conclusions: These findings indicate that RAGE/ligand interaction plays a key role in neointimal formation after vascular injury irrespective of diabetes status and suggest a novel target to minimize neointimal hyperplasia.

MeSH terms

  • Angioplasty, Balloon / adverse effects
  • Animals
  • Arterial Occlusive Diseases / blood
  • Arterial Occlusive Diseases / etiology*
  • Arterial Occlusive Diseases / pathology
  • Blood Glucose / analysis
  • Cell Division / drug effects
  • Cells, Cultured
  • Glycation End Products, Advanced / analysis
  • Glycation End Products, Advanced / immunology
  • Immunohistochemistry
  • Kinetics
  • Leukocyte L1 Antigen Complex / analysis
  • Leukocyte L1 Antigen Complex / immunology
  • Ligands
  • Lipids / blood
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / pathology
  • Rats
  • Rats, Zucker
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic / analysis
  • Receptors, Immunologic / immunology
  • Receptors, Immunologic / physiology*

Substances

  • Blood Glucose
  • Glycation End Products, Advanced
  • Leukocyte L1 Antigen Complex
  • Ligands
  • Lipids
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic